-

MedX Announces Board Changes

MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. (“MedX” or the “Company”) (MDX – TSXV), announces that at the Annual and Special General Meeting of shareholders held on August 16, 2021, Rob von der Porten retired as a director, thus creating a vacancy on the Board. Mr. von der Porten had been not only Chairman of the Board, but also acting as Chief Executive Officer during the last fifteen-month period that MedX was conducting a search for a new CEO. Ken McKay has been appointed as Chairman of the Board. In addition, Sylvain Desjeans, recently promoted to President and CEO of MedX, has been appointed to the Board to fill the vacancy created by the retirement of Mr. von der Porten.

“The Board thanks Rob for his service and leadership during a period of over seven years, during which time the Company has developed into being a leading medical device and software company. During his tenure, MedX completed the development of its SIAscopy™ on DermSecureTM Telemedicine platform.” stated Mr. McKay

“I am proud to have worked with my MedX colleagues who are so committed to the development of the SIAscopy™ technology and the DermSecureTM Telemedicine platform,” said Mr. von der Porten. “It represents a significant leap forward for early detection of skin cancers as well as the assessment of other skin conditions with the addition of its high-definition camera. I am confident that the Company will leverage its technology across North America and internationally to achieve great commercial success” he continued.

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy™ on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy™ is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. Visit https://medxhealth.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.

Contacts

Bill Mitoulas, Investor Relations
MedX Health Corp
+1.416.479.9547
bill@medxhealth.com

Industry:

MedX Health Corp.

TSX VENTURE:MDX
Release Versions
English

Contacts

Bill Mitoulas, Investor Relations
MedX Health Corp
+1.416.479.9547
bill@medxhealth.com

More News From MedX Health Corp.

MedX Announces $2,700,000 Initial Closing of Non-Brokered Private Placement of Series IV Convertible Loan Notes

MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that, further to its Press Release dated February 2, 2026, it has surpassed the Minimum Subscription and closed on an Initial Closing of $2,700,000 of the non-brokered Private Placement to accredited investors. The Private Placement is for up to $5,000,000 by issuance of up to 100 Convertible Loan Notes, each with a face value of $50,000 (“Series IV Notes”). The Series IV Notes...

MedX Announces Non-Brokered Private Placement of Series IV Convertible Loan Notes

MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that it is proposing a non-brokered Private Placement to accredited investors of up to $5 million by issuance of up to 100 Convertible Loan Notes, each with a face value of $50,000 (“Series IV Notes”). The Series IV Notes will bear interest at 6% per year, payable Quarterly, and will mature on December 31, 2028 (the “Maturity Date”). The Series IV Notes may be converted, at the...

MedX Health 2025 YEAR REVIEW

MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. (TSXV: MDX) (“MedX” or the “Company”) is a data-driven health analytics business underpinned by proprietary intellectual property and regulated medical technologies. MedX’s platform generates and analyses high-fidelity skin health data using patented imaging, Teledermatology, and Photobiomodulation systems, creating a growing, defensible data asset and IP moat. MedX operates as an ISO 13485–certified medical device manufacturer and mainta...
Back to Newsroom